Histopathological findings in extended prostate biopsy with PSA ≤ 4 ng/mL
OBJECTIVE: Cancer detection has been reported in up to 27% of patients when lowering the PSA cutoff to 2.5 ng/mL. Although this practice could increase the number of biopsies performed, it also could lead to more frequent detection of significant prostate cancers at an organ-confined stage and/or a less aggressive state. This study describes the incidence of malignancy and tumor characteristics in extended prostate biopsies with PSA ≤ 4 ng/mL. MATERIALS AND METHODS: Prostate biopsies from 1081 patients where examined, 275 (25.4%) patients had PSA level ≤ 4 ng/mL. RESULTS: Cancer was diagnosed in 32.0% and 35.7% of patients with PSA ≤ 4 ng/mL and > 4 ng/mL, respectively (p = 0.906). The median Gleason score was 7 independent of PSA > or ≤ 4 ng/mL (p = 0.078). The median number of cores positive for tumor was 4 and 3, respectively, for PSA > 4 ng/mL and PSA ≤ 4 ng/mL (p = 0.627). There was a difference in the total percent of tumors involving all cores, 11% and 7% for PSA > or ≤ 4 ng/mL (p = 0.042). Fifty-six patients underwent radical prostatectomy, 12 had PSA ≤ 4 ng/mL. In both groups, a diagnosis of cancer was accurate with no differences in Gleason score, tumor volume or staging for both groups. CONCLUSION: When PSA is below 4 ng/mL, cancer is detected in a proportion equal to the proportion diagnosed with a PSA > 4 ng/mL, and tumor characteristics are similar between the two groups. Only clinically significant tumors were diagnosed following radical prostatectomy.
Main Authors: | , , , , |
---|---|
Format: | Digital revista |
Language: | English |
Published: |
Sociedade Brasileira de Urologia
2008
|
Online Access: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382008000300005 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
oai:scielo:S1677-55382008000300005 |
---|---|
record_format |
ojs |
spelling |
oai:scielo:S1677-553820080003000052008-09-23Histopathological findings in extended prostate biopsy with PSA ≤ 4 ng/mLLeite,Katia R.Srougi,MiguelDall'Oglio,Marcos F.Sanudo,AdrianaCamara-Lopes,Luiz H. PSA prostate cancer biopsy diagnosis Gleason score tumor volume OBJECTIVE: Cancer detection has been reported in up to 27% of patients when lowering the PSA cutoff to 2.5 ng/mL. Although this practice could increase the number of biopsies performed, it also could lead to more frequent detection of significant prostate cancers at an organ-confined stage and/or a less aggressive state. This study describes the incidence of malignancy and tumor characteristics in extended prostate biopsies with PSA ≤ 4 ng/mL. MATERIALS AND METHODS: Prostate biopsies from 1081 patients where examined, 275 (25.4%) patients had PSA level ≤ 4 ng/mL. RESULTS: Cancer was diagnosed in 32.0% and 35.7% of patients with PSA ≤ 4 ng/mL and > 4 ng/mL, respectively (p = 0.906). The median Gleason score was 7 independent of PSA > or ≤ 4 ng/mL (p = 0.078). The median number of cores positive for tumor was 4 and 3, respectively, for PSA > 4 ng/mL and PSA ≤ 4 ng/mL (p = 0.627). There was a difference in the total percent of tumors involving all cores, 11% and 7% for PSA > or ≤ 4 ng/mL (p = 0.042). Fifty-six patients underwent radical prostatectomy, 12 had PSA ≤ 4 ng/mL. In both groups, a diagnosis of cancer was accurate with no differences in Gleason score, tumor volume or staging for both groups. CONCLUSION: When PSA is below 4 ng/mL, cancer is detected in a proportion equal to the proportion diagnosed with a PSA > 4 ng/mL, and tumor characteristics are similar between the two groups. Only clinically significant tumors were diagnosed following radical prostatectomy.info:eu-repo/semantics/openAccessSociedade Brasileira de UrologiaInternational braz j urol v.34 n.3 20082008-06-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382008000300005en10.1590/S1677-55382008000300005 |
institution |
SCIELO |
collection |
OJS |
country |
Brasil |
countrycode |
BR |
component |
Revista |
access |
En linea |
databasecode |
rev-scielo-br |
tag |
revista |
region |
America del Sur |
libraryname |
SciELO |
language |
English |
format |
Digital |
author |
Leite,Katia R. Srougi,Miguel Dall'Oglio,Marcos F. Sanudo,Adriana Camara-Lopes,Luiz H. |
spellingShingle |
Leite,Katia R. Srougi,Miguel Dall'Oglio,Marcos F. Sanudo,Adriana Camara-Lopes,Luiz H. Histopathological findings in extended prostate biopsy with PSA ≤ 4 ng/mL |
author_facet |
Leite,Katia R. Srougi,Miguel Dall'Oglio,Marcos F. Sanudo,Adriana Camara-Lopes,Luiz H. |
author_sort |
Leite,Katia R. |
title |
Histopathological findings in extended prostate biopsy with PSA ≤ 4 ng/mL |
title_short |
Histopathological findings in extended prostate biopsy with PSA ≤ 4 ng/mL |
title_full |
Histopathological findings in extended prostate biopsy with PSA ≤ 4 ng/mL |
title_fullStr |
Histopathological findings in extended prostate biopsy with PSA ≤ 4 ng/mL |
title_full_unstemmed |
Histopathological findings in extended prostate biopsy with PSA ≤ 4 ng/mL |
title_sort |
histopathological findings in extended prostate biopsy with psa ≤ 4 ng/ml |
description |
OBJECTIVE: Cancer detection has been reported in up to 27% of patients when lowering the PSA cutoff to 2.5 ng/mL. Although this practice could increase the number of biopsies performed, it also could lead to more frequent detection of significant prostate cancers at an organ-confined stage and/or a less aggressive state. This study describes the incidence of malignancy and tumor characteristics in extended prostate biopsies with PSA ≤ 4 ng/mL. MATERIALS AND METHODS: Prostate biopsies from 1081 patients where examined, 275 (25.4%) patients had PSA level ≤ 4 ng/mL. RESULTS: Cancer was diagnosed in 32.0% and 35.7% of patients with PSA ≤ 4 ng/mL and > 4 ng/mL, respectively (p = 0.906). The median Gleason score was 7 independent of PSA > or ≤ 4 ng/mL (p = 0.078). The median number of cores positive for tumor was 4 and 3, respectively, for PSA > 4 ng/mL and PSA ≤ 4 ng/mL (p = 0.627). There was a difference in the total percent of tumors involving all cores, 11% and 7% for PSA > or ≤ 4 ng/mL (p = 0.042). Fifty-six patients underwent radical prostatectomy, 12 had PSA ≤ 4 ng/mL. In both groups, a diagnosis of cancer was accurate with no differences in Gleason score, tumor volume or staging for both groups. CONCLUSION: When PSA is below 4 ng/mL, cancer is detected in a proportion equal to the proportion diagnosed with a PSA > 4 ng/mL, and tumor characteristics are similar between the two groups. Only clinically significant tumors were diagnosed following radical prostatectomy. |
publisher |
Sociedade Brasileira de Urologia |
publishDate |
2008 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382008000300005 |
work_keys_str_mv |
AT leitekatiar histopathologicalfindingsinextendedprostatebiopsywithpsa4ngml AT srougimiguel histopathologicalfindingsinextendedprostatebiopsywithpsa4ngml AT dallogliomarcosf histopathologicalfindingsinextendedprostatebiopsywithpsa4ngml AT sanudoadriana histopathologicalfindingsinextendedprostatebiopsywithpsa4ngml AT camaralopesluizh histopathologicalfindingsinextendedprostatebiopsywithpsa4ngml |
_version_ |
1756428023925571584 |